Drug or technology
7 developments in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Latest
Everything in the corpus, newest first.
SEP 9, 2026 · PHASE 3 TRIAL
ClinicalTrials.gov
This is a Phase 3 registry record with no reported results; the study is active but not recruiting, so outcomes remain unreported in this source.
AUG 19, 2026 · INTERVENTIONAL STUDY
ClinicalTrials.gov
This is a registered interventional study not yet recruiting with no posted results; it represents planned work to test whether semaglutide plus counselling improves alcohol abstinence versus counselling alone in patients with obesity and fatty liver disease.
AUG 18, 2026 · PHASE 3 TRIAL
ClinicalTrials.gov
Phase 3 trial with completed recruitment (n=23) examining surrogate immune endpoints in Alzheimer's disease; no results posted in this registry record.
AUG 14, 2026 · PHASE 4 TRIAL
ClinicalTrials.gov
This is a completed Phase 4 registry record with no posted results; the study design and primary endpoint are stated but outcomes remain unreported.
AUG 10, 2026 · PHASE 2 TRIAL
ClinicalTrials.gov
Phase 2 interventional trial in recruitment with no posted results; represents early-stage efficacy and safety testing of an investigational drug combination.
This is an actively recruiting Phase 3 trial with no results posted; the registry record describes planned design and endpoints only.
JUN 18, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of manufacturing changes for Wegovy; no clinical efficacy or safety data are reported in this regulatory action.